What's in CMC Ambroise Paré's pipeline?

CMC Ambroise Paré has 3 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with CMC Ambroise Paré's portfolio?

Top competitors by shared drug class: Amgen, Celltrion, Sandoz.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/cmc-ambroise-par.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

CMC Ambroise Paré — Portfolio Competitive Intelligence Brief

CMC Ambroise Paré pipeline: 1 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
inert tablet	inert tablet	marketed
CT-P13	CT-P13	phase 3	TNF-α inhibitor (biosimilar)	TNF-α (tumor necrosis factor-alpha)	Immunology / Rheumatology

Therapeutic area mix

Immunology / Rheumatology · 1
Respiratory · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Amgen · 1 shared drug class
Celltrion · 1 shared drug class
Sandoz · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CMC Ambroise Paré:

Cite this brief

Drug Landscape (2026). CMC Ambroise Paré — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cmc-ambroise-par. Accessed 2026-05-16.